Rossella Scardaci

Dr. Rossella Scardaci

University of Turin
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2024 in Molecular Oncology
Verified
Journal Article
Open access
RSRossella Scardaci
Rossella Scardaci
EBEwa Berlinska
Ewa Berlinska
PSPietro Scaparone
Pietro Scaparone
SMSandra Vietti Michelina
Sandra Vietti Michelina
EGEdoardo Garbo
Edoardo Garbo
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
Mutations in the RAS–RAF–MEK–ERK pathway are frequent alterations in cancer and RASopathies, and while RAS oncogene activation alone affects 19% of all patients and accounts for approximately 3.4 million new cases every year, less frequent alterations in the cascade's downstream effectors are also involved in cancer etiology. RAS proteins initiate the signaling cascade by promoting the dimerization of RAF kinases, which can act as oncoproteins as well: BRAFV600E is the most common oncogenic driver, mutated in the 8% of all malignancies. Research in this field led to the development of drugs that target the BRAFV600‐like mutations (Class I), which are now utilized in clinics, but cause paradoxical activation of the pathway and resistance development. Furthermore, they are ineffective against non‐BRAFV600E malignancies that dimerize and could be either RTK/RAS independent or dependent (Class II and III, respectively), which are still lacking an effective treatment. This review discusses the recent advances in anti‐RAF therapies, including paradox breakers, dimer‐inhibitors, immunotherapies, and other novel approaches, critically evaluating their efficacy in overcoming the therapeutic limitations, and their putative role in blocking the RAS pathway.

27 March 2022 in Microbiological Research
Verified
Journal Article
Closed access
SDSophie Michelle DOUBLIER
Sophie Michelle DOUBLIER
SCSimona Cirrincione
Simona Cirrincione
RSRossella Scardaci
Rossella Scardaci
CBC. Botta
C. Botta
CLCristina Lamberti
Cristina Lamberti
EPEnrica Pessione
Enrica Pessione

22 February 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
RSRossella Scardaci
Rossella Scardaci
FBFrancesca Bietto
Francesca Bietto
PRPierre-Jean Racine
Pierre-Jean Racine
ABAmine Boukerb
Amine Boukerb
OLOlivier Lesouhaitier
Olivier Lesouhaitier
EPEnrica Pessione
Enrica Pessione
The human gut microbiota has co-evolved with humans by exchanging bidirectional signals. This study aims at deepening the knowledge of this crucial relationship by analyzing phenotypic and interactive responses of the probiotic Enterococcus faecium NCIMB10415 (E. faecium SF68) to the top-down signals norepinephrine (NE) and serotonin (5HT), two neuroactive molecules abundant in the gut. We treated E. faecium NCIMB10415 with 100 µM NE and 50 µM 5HT and tested its ability to form static biofilm (Confocal Laser Scanning Microscopy), adhere to the Caco-2/TC7 monolayer, affect the epithelial barrier function (Transepithelial Electrical Resistance) and human dendritic cells (DC) maturation, differentiation, and cytokines production. Finally, we evaluated the presence of a putative hormone sensor through in silico (whole genome sequence and protein modelling) and in vitro (Micro-Scale Thermophoresis) analyses. The hormone treatments increase biofilm formation and adhesion on Caco-2/TC7, as well as the epithelial barrier function. No differences concerning DC differentiation and maturation between stimulated and control bacteria were detected, while an enhanced TNF-α production was observed in NE-treated bacteria. Investigations on the sensor support the hypothesis that a two-component system on the bacterial surface can sense 5HT and NE. Overall, the data demonstrate that E. faecium NCIMB10415 can sense both NE and 5HT and respond accordingly.

1 January 2021 in Journal of Proteomics
Verified
Journal Article
Closed access
RSRossella Scardaci
Rossella Scardaci
FVF. Varese
F. Varese
MMM. Manfredi
M. Manfredi
EME. Marengo
E. Marengo
RMR. Mazzoli
R. Mazzoli
EPEnrica Pessione
Enrica Pessione

26 July 2021 in Microbiology Research
Verified
Journal Article
Open access
PDF file
RSRossella Scardaci
Rossella Scardaci
MMarcello Manfredi
Marcello Manfredi
EBElettra Barberis
Elettra Barberis
SSSara Scutera
Sara Scutera
EMEmílio Marengo
Emílio Marengo
EPEnrica Pessione
Enrica Pessione
The role of the microbiota–gut–brain axis in maintaining a healthy status is well recognized. In this bidirectional flux, the influence of host hormones on gut bacteria is crucial. However, data on commensal/probiotics are scarce since most reports analyzed the effects of human bioactive compounds on opportunistic strains, highlighting the risk of increased pathogenicity under stimulation. The present investigation examined the modifications induced by 5HT, a tryptophan-derived molecule abundant in the intestine, on the probiotic Enterococcus faecium NCIMB10415. Specific phenotypic modifications concerning the probiotic potential and possible effects of treated bacteria on dendritic cells were explored together with the comparative soluble proteome evaluation. Increased resistance to bile salts and ampicillin in 5HT-stimulated conditions relate with overexpression of specific proteins (among which Zn-beta-lactamases, a Zn-transport protein and a protein involved in fatty acid incorporation into the membrane). Better auto-aggregating properties and biofilm-forming aptitude are consistent with enhanced QS peptide transport. Concerning interaction with the host, E. faecium NCIMB10415 enhanced dendritic cell maturation, but no significant differences were observed between 5HT-treated and untreated bacteria; meanwhile, after 5HT exposure, some moonlight proteins possibly involved in tissue adhesion were found in higher abundance. Finally, the finding in stimulated conditions of a higher abundance of VicR, a protein involved in two-component signal transduction system (VicK/R), suggests the existence of a possible surface receptor (VicK) for 5HT sensing in the strain studied. These overall data indicate that E. faecium NCIMB10415 modifies its physiology in response to 5HT by improving bacterial interactions and resistance to stressors.

22 June 2026 in Cancer Discovery
Verified
Journal Article
Closed access
PSPietro Scaparone
Pietro Scaparone
AMAlessia Mira
Alessia Mira
TCTaek-Chin Cheong
Taek-Chin Cheong
EPEnrico Patrucco
Enrico Patrucco
BRBiagio Ricciuti
Biagio Ricciuti
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
KRAS mutations are common oncogenic drivers in human cancers, with the KRASG12C variant being a key target in lung adenocarcinoma. Despite the FDA approval of KRASG12C-selective inhibitors, their clinical efficacy has been limited, as evidenced by trials showing modest response rates and resistance development through the selection of acquired genomic alterations. Our study explores the mechanisms underlying acquired EML4–ALK fusion in KRASG12C-driven tumors developing resistance to KRASG12C inhibitors and potential therapeutic strategies to overcome it. Our findings reveal that combined ALK/KRASG12C inhibition is an effective therapeutic approach in this context. Moreover, we observed that KRASG12C/EML4–ALK tumor cells kept under constant pressure with KRASG12C inhibitors exhibit sensitivity to single-agent ALK inhibitors, suggesting a potential for rationally designed sequential treatments. Mechanistically, EML4–ALK bypasses KRASG12C inhibition by activating wild-type RAS, highlighting an additional therapeutic opportunity for multiselective RAS inhibitors under clinical investigation. Significance: Acquired EML4–ALK fusions confer resistance to KRAS inhibition in KRASG12C-driven lung adenocarcinoma. By rewiring the oncogenic signaling under inhibitor pressure, EML4–ALK creates a new oncogenic dependency that can be exploited for more effective therapeutic strategies. See related commentary by Araujo and Skoulidi, p. 2206